Home / Business and Economy / India Poised to Lead Global GLP-1 Generics
India Poised to Lead Global GLP-1 Generics
22 Feb
Summary
- Semaglutide patent expiry in India in 2026 sparks generic revolution.
- Millions more patients to gain access to GLP-1 therapies.
- Indian firms set to become major global suppliers of generics.
The year 2026 is anticipated to mark a significant turning point for GLP-1 therapies in India, as the active ingredient semaglutide is expected to lose its patent protection. This event is poised to transition these treatments from a premium, niche intervention to a widely scalable and accessible solution for a much larger patient population.
Industry experts estimate this change could bring an additional 120,000 to 150,000 patients into the fold for both diabetes and weight management. A substantial majority of India's GLP-1 pipeline is focused on semaglutide, reflecting strong confidence in its future affordability and widespread availability.
Furthermore, Indian pharmaceutical manufacturers are strategically preparing to serve as global suppliers for semaglutide generics. They are targeting entry into more than 80 international markets, indicating a significant expansion of India's role in the worldwide pharmaceutical landscape.
